Shan Xu

7.0k total citations · 1 hit paper
171 papers, 5.6k citations indexed

About

Shan Xu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shan Xu has authored 171 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Molecular Biology, 42 papers in Pulmonary and Respiratory Medicine and 34 papers in Oncology. Recurrent topics in Shan Xu's work include PI3K/AKT/mTOR signaling in cancer (22 papers), Lung Cancer Treatments and Mutations (19 papers) and Synthesis and biological activity (16 papers). Shan Xu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (22 papers), Lung Cancer Treatments and Mutations (19 papers) and Synthesis and biological activity (16 papers). Shan Xu collaborates with scholars based in China, United States and Taiwan. Shan Xu's co-authors include Mariusz Karbowski, Der‐Fen Suen, Megan M. Cleland, Derek P. Narendra, Atsushi Tanaka, Richard J. Youle, Pengwu Zheng, Dalin He, Wufu Zhu and Peng Guo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Shan Xu

162 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin

2010 1.1k citations Shan Xu, Mariusz Karbowski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shan Xu China	35	3.3k	1.1k	726	606	602	171	5.6k
Thomas C. Chen United States	43	2.3k 0.7×	1.2k 1.1×	268 0.4×	893 1.5×	665 1.1×	176	5.9k
Sujit K. Bhutia India	50	4.1k 1.3×	2.0k 1.8×	416 0.6×	1.4k 2.3×	1.2k 2.0×	165	7.8k
Xianming Deng China	44	3.7k 1.1×	310 0.3×	978 1.3×	545 0.9×	358 0.6×	145	6.5k
Karin Öllinger Sweden	35	2.8k 0.8×	1.1k 1.0×	355 0.5×	351 0.6×	387 0.6×	86	5.2k
Axel H. Schönthal United States	54	4.6k 1.4×	1.2k 1.1×	432 0.6×	1.6k 2.6×	937 1.6×	170	8.1k
Florence Lefranc Belgium	42	2.5k 0.8×	1.4k 1.2×	923 1.3×	666 1.1×	545 0.9×	108	6.3k
Takuya Noguchi Japan	40	3.8k 1.2×	576 0.5×	211 0.3×	408 0.7×	959 1.6×	135	6.1k
Qian Wang China	39	4.2k 1.3×	367 0.3×	382 0.5×	833 1.4×	1.5k 2.5×	263	6.3k
Ziwei Huang United States	38	5.6k 1.7×	328 0.3×	980 1.3×	1.0k 1.7×	441 0.7×	146	7.6k
Ismael Samudio United States	47	3.9k 1.2×	525 0.5×	347 0.5×	1.5k 2.5×	1.3k 2.2×	95	6.8k

Countries citing papers authored by Shan Xu

Since Specialization

Citations

This map shows the geographic impact of Shan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shan Xu more than expected).

Fields of papers citing papers by Shan Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shan Xu. The network helps show where Shan Xu may publish in the future.

Co-authorship network of co-authors of Shan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Shan Xu. A scholar is included among the top collaborators of Shan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shan Xu. Shan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Bohan, Mingming Lu, Shan Xu, et al.. (2025). A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition. Cancer Research. 85(18). 3490–3502.

Guo, Qiuyan, Shan Xu, Dan Qiao, et al.. (2024). Space-confined nanozyme with cascade reaction based on PCN-224 for synergistic bacterial infection treatment and NIR fluorescence imaging of wound bacterial infections. Chemical Engineering Journal. 487. 150642–150642. 21 indexed citations

Wang, Linxiao, Xiaoling Huang, Yufeng An, et al.. (2024). Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R. BMC Chemistry. 18(1). 159–159. 1 indexed citations

Yang, Yang, Mengting Yu, Li Fu, et al.. (2023). Based on virtual screening methods and biological activity assessment, AK-968/13030056 has been identified as a potential mTOR inhibitor. Journal of Molecular Structure. 1302. 137425–137425. 4 indexed citations

Xie, Zhouling, Jiaojiao Guo, Yan Li, et al.. (2023). T5S1607 identified as a antibacterial FtsZ inhibitor：Virtual screening combined with bioactivity evaluation for the drug discovery. Computational Biology and Chemistry. 108. 108006–108006. 4 indexed citations

Zhang, Jianqing, Han Zhang, Sheng Tang, et al.. (2023). Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents. European Journal of Medicinal Chemistry. 257. 115499–115499. 9 indexed citations

Zhao, Yang, Jiaqi Chen, Tianjie Liu, et al.. (2023). Knocking down AR promotes osteoblasts to recruit prostate cancer cells by altering exosomal circ-DHPS/miR-214-3p/CCL5 pathway. Asian Journal of Andrology. 26(2). 195–204. 7 indexed citations

Tang, Sheng, Wenhui Gan, Linxiao Wang, et al.. (2023). Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC. European Journal of Medicinal Chemistry. 263. 115939–115939. 11 indexed citations

Xu, Shan, Xin Sun, Yang Yang, et al.. (2022). XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer. Biomedicine & Pharmacotherapy. 155. 113537–113537. 17 indexed citations

10.

Xiao, Zhen, Zhihui Zhou, Qian Zhang, et al.. (2020). Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. Bioorganic & Medicinal Chemistry. 28(19). 115669–115669. 25 indexed citations

11.

Guan, Bing, Kaijie Wu, Jin Zeng, et al.. (2016). Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget. 8(5). 8162–8172. 55 indexed citations

12.

Zhu, Wufu, Wenhui Wang, Shan Xu, et al.. (2016). Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Bioorganic & Medicinal Chemistry. 24(8). 1749–1756. 36 indexed citations

13.

Zhu, Wufu, Wenhui Wang, Shan Xu, et al.. (2016). Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Bioorganic & Medicinal Chemistry. 24(4). 812–819. 24 indexed citations

14.

Xu, Shan, Zheng Yang, Yizeng Fan, et al.. (2016). Curcumin enhances temsirolimus-induced apoptosis in human renal carcinoma cells through upregulation of YAP/p53. Oncology Letters. 12(6). 4999–5006. 28 indexed citations

15.

Chen, Zhiliang, Yongwang Zhong, Yang Wang, et al.. (2013). Correction: Ubiquitination-Induced Fluorescence Complementation (UiFC) for Detection of K48 Ubiquitin Chains In Vitro and in Live Cells. PLoS ONE. 8(9).

16.

Guan, Zhenfeng, Chen Ding, Yiqing Du, et al.. (2013). HAF drives the switch of HIF-1α to HIF-2α by activating the NF-κB pathway, leading to malignant behavior of T24 bladder cancer cells. International Journal of Oncology. 44(2). 393–402. 34 indexed citations

17.

Wang, Chunliang, et al.. (2010). [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].. PubMed. 39(3). 156–60. 12 indexed citations

18.

Xu, Shan, Guihong Peng, Yang Wang, Shengyun Fang, & Mariusz Karbowski. (2010). The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover. Molecular Biology of the Cell. 22(3). 291–300. 211 indexed citations

19.

Zhu, Xiaomei, Yong-ming Yao, Huaping Liang, et al.. (2009). The Effect of High Mobility Group Box-1 Protein on Splenic Dendritic Cell Maturation in Rats. Journal of Interferon & Cytokine Research. 29(10). 677–686. 34 indexed citations

20.

Ariizumi, Kiyoshi, Sojin Shikano, Shan Xu, et al.. (2000). Identification of a Novel, Dendritic Cell-associated Molecule, Dectin-1, by Subtractive cDNA Cloning. Journal of Biological Chemistry. 275(26). 20157–20167. 366 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact